Placenta Accreta

Comprehensive Clinical Guide: Placenta Accreta Spectrum (PAS)

Placenta Accreta Spectrum (PAS) represents one of the most significant obstetric challenges in modern maternal-fetal medicine. Historically referred to as "morbidly adherent placenta," this condition occurs when the placenta attaches too deeply into the uterine wall. Unlike a normal placenta, which attaches to the uterine lining (decidua basalis) and separates easily after delivery, PAS involves an abnormal adherence that can lead to life-threatening hemorrhage during the third stage of labor.

1. Clinical Definition and Overview

Placenta Accreta Spectrum is defined by the abnormal adherence of the placenta to the myometrium, caused by a partial or total absence of the decidua basalis and a defective Nitabuch’s layer. The clinical severity is categorized by the depth of placental invasion:

• Placenta Accreta (Vera): The chorionic villi attach directly to the myometrium without invading the muscle.
• Placenta Increta: The chorionic villi invade into the myometrium.
• Placenta Percreta: The chorionic villi penetrate through the uterine serosa and may involve adjacent pelvic organs, most commonly the urinary bladder.

2. Pathophysiology and Etiology

The primary mechanism underlying PAS is the failure of the decidua basalis to form a protective barrier between the placental villi and the myometrium.

The Role of Uterine Scarring

The most significant risk factor for PAS is the presence of a uterine scar, typically from a prior Cesarean section, in the context of a low-lying placenta or placenta previa. When the blastocyst implants over a previous hysterotomy scar, the decidua is often deficient or absent. This allows the trophoblastic cells to invade directly into the underlying myometrium.

Molecular Mechanisms

Recent research suggests that excessive trophoblast invasion is driven by:
1. Angiogenic Imbalance: Altered expression of VEGF (Vascular Endothelial Growth Factor) and placental growth factors.
2. Matrix Metalloproteinases (MMPs): Overexpression of MMPs, which degrade the extracellular matrix, facilitating deep tissue invasion.
3. Defective Decidualization: Impaired transformation of the endometrial stromal cells, which normally act as a "gatekeeper" to limit trophoblast growth.

3. Clinical Staging and Grading

The International Federation of Gynecology and Obstetrics (FIGO) has established a clinical grading system to standardize the management of PAS, which relies on both histological findings and the depth of invasion observed during surgery.

4. Standard Presentation and Diagnosis

PAS is rarely symptomatic during pregnancy. However, it is a high-risk condition that requires rigorous screening.

Clinical Presentation

• Asymptomatic: Most patients are diagnosed via routine ultrasound.
• Vaginal Bleeding: Painless, bright red vaginal bleeding in the third trimester is a common sign when associated with placenta previa.
• Hematuria: In cases of percreta invading the bladder, hematuria may occur.

Key Diagnostic Tests

The "Gold Standard" for diagnosis is high-resolution transvaginal and transabdominal ultrasound performed by an expert sonographer.

1. Ultrasound Markers:
   • Loss of the "clear space" (the hypoechoic retroplacental zone).
   • Placental lacunae ("Swiss cheese" appearance).
   • Bladder wall interruption.
   • Myometrial thinning (<1mm).
2. Color Doppler Mapping:
   • Hypervascularity of the uterine-placental interface.
   • Bridging vessels extending from the placenta to the uterine wall.
3. Magnetic Resonance Imaging (MRI): Used primarily when ultrasound findings are equivocal or to assess the depth of invasion (especially in posterior placentas or suspicion of percreta).

5. Differential Diagnosis

It is critical to distinguish PAS from other obstetric complications that mimic its presentation:
* Placenta Previa: Can exist without accreta; differentiation relies on the presence of retroplacental clear space.
* Placental Abruption: Characterized by pain and uterine tenderness, whereas PAS is usually painless.
* Uterine Leiomyoma: Can sometimes mimic the appearance of placental lacunae on ultrasound.
* Normal Placenta with Low Implantation: Requires careful assessment of the placental-myometrial interface.

6. Management and Surgical Indications

Management of PAS requires a multidisciplinary team (MDT) approach, including obstetricians, gynecologic oncologists, urologists, interventional radiologists, and specialized anesthesiologists.

Standard of Care: Cesarean Hysterectomy

The current gold standard for the management of PAS is a planned Cesarean Hysterectomy with the placenta left in situ. Attempting to manually remove a morbidly adherent placenta carries a high risk of catastrophic hemorrhage, disseminated intravascular coagulation (DIC), and death.

Conservative Management (Expectant Management)

In select cases where the patient strongly desires future fertility, the placenta may be left in situ after the delivery of the fetus.
* Indications: Focal accreta, stable patient, no signs of infection.
* Risks: Delayed hemorrhage, severe sepsis, and pulmonary embolism.
* Adjuncts: Methotrexate is sometimes used, though its efficacy is debated and not routinely recommended due to toxicity and lack of proven benefit.

7. Risks, Side Effects, and Prognosis

Maternal Risks

• Massive Hemorrhage: Average blood loss often exceeds 3,000–5,000 mL.
• Ureteric Injury: Increased risk due to distorted pelvic anatomy.
• Multiorgan Failure: Secondary to hypovolemic shock.
• Psychological Trauma: Associated with emergency hysterectomy and intensive care admission.

Long-term Prognosis

Patients who undergo hysterectomy have an excellent survival rate, though they face permanent infertility. Those who undergo conservative management require long-term follow-up to ensure the placenta is resorbed without complications such as pyometra or secondary hemorrhage.

8. Massive FAQ Section: Placenta Accreta

1. Is Placenta Accreta preventable?

There is no definitive way to prevent PAS, but the risk can be significantly reduced by minimizing the number of Cesarean sections and avoiding unnecessary uterine instrumentation.

2. Can I have a vaginal birth with Placenta Accreta?

No. Attempting a vaginal delivery with a diagnosed PAS is contraindicated due to the extreme risk of life-threatening hemorrhage during the placental separation phase.

3. How early is PAS usually detected?

With high-quality prenatal care, PAS is often identified during the 18–20 week anatomy scan or a follow-up third-trimester scan for placenta previa.

4. Does having PAS mean I will lose my uterus?

In the vast majority of cases, a Cesarean hysterectomy is the safest option. While conservative management is possible, it carries significant risks of infection and delayed hemorrhage.

5. Does the depth of invasion affect my recovery time?

Yes. A percreta involving the bladder or surrounding structures requires a more extensive surgery, potentially involving cystotomy or ureteral stenting, which increases recovery time and morbidity.

6. Is MRI better than ultrasound for diagnosis?

Ultrasound is the first-line screening tool. MRI is complementary and is most useful for assessing the extent of invasion (staging) rather than the initial diagnosis.

7. What are "placental lacunae"?

These are large, irregular, blood-filled spaces within the placenta that appear as dark, "Swiss cheese-like" voids on ultrasound, indicating high-flow vascular channels.

8. What is the role of Interventional Radiology (IR)?

IR can be used to place prophylactic balloon catheters in the internal iliac arteries. These can be inflated during surgery to reduce blood flow to the uterus, though evidence on their efficacy is mixed.

9. Can I become pregnant again after a hysterectomy?

No, a hysterectomy involves the removal of the uterus, which terminates fertility. Patients who desire future children may look into gestational surrogacy.

10. How high is the maternal mortality rate for PAS?

In developed countries with access to multidisciplinary care, maternal mortality is relatively low (approx. 1–3%), but maternal morbidity remains very high due to surgical complications.

9. Clinical Summary Table: Management Strategy

Concluding Expert Note

The management of Placenta Accreta Spectrum has evolved from a "watch and wait" approach to a highly structured, surgical-heavy intervention. The cornerstone of success is early diagnosis and delivery at a tertiary care center equipped with a massive transfusion protocol and surgical subspecialists. Clinicians should maintain a high index of suspicion for any patient with a history of Cesarean delivery and a placenta previa or low-lying placenta.